Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Pharmacol Rep ; 76(1): 72-85, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38180634

ABSTRACT

BACKGROUND: Chronic pain is a major health problem that affects a significant number of patients, resulting in personal suffering and substantial health care costs. One of the most commonly reported causal conditions is osteoarthritis (OA). In addition to sensory symptoms, chronic pain shares an inherent overlap with mood or anxiety disorders. The involvement of the frontal cortex, striatum and nucleus accumbens, in the affective processing of pain is still poorly understood. METHODS: Male Wistar rats were divided into two groups: MIA (monoiodoacetate injected into the knee-model of OA) and sham (NaCl). Behavioral tests assessing pain, anxiety, and depressive behavior were performed at week 1, 3, 4, 6, 8, and 10. Neurochemical assays were conducted at weeks 3, 6, and 10 post-MIA injection, followed by the neurotransmitters and their metabolites correlation matrix and network analysis. RESULTS: OA animals developed rapid pain phenotype, whereas anxiety-like behavior accompanied the development of a pain phenotype from 6 week post-MIA injection. We did not detect any depressive-like behavior. Instead, immobility time measured in the forced swimming test transiently decreased at 3 weeks post-MIA in the OA group. We detected changes in noradrenaline and serotonin levels in analyzed structures at distinct time points. Network analysis revealed noradrenaline and serotonin neurotransmission changes in the nucleus accumbens, confirming it to be the key structure affected by chronic pain. CONCLUSION: Animals with chronic pain exhibit symptoms of anxiety-like behavior and we identified underlying neurochemical changes using network analysis.


Subject(s)
Chronic Pain , Osteoarthritis , Humans , Rats , Male , Animals , Rats, Wistar , Serotonin , Norepinephrine/metabolism , Anxiety , Disease Models, Animal
2.
Int J Mol Sci ; 23(11)2022 May 25.
Article in English | MEDLINE | ID: mdl-35682647

ABSTRACT

Mental illness modeling is still a major challenge for scientists. Animal models of schizophrenia are essential to gain a better understanding of the disease etiopathology and mechanism of action of currently used antipsychotic drugs and help in the search for new and more effective therapies. We can distinguish among pharmacological, genetic, and neurodevelopmental models offering various neuroanatomical disorders and a different spectrum of symptoms of schizophrenia. Modeling schizophrenia is based on inducing damage or changes in the activity of relevant regions in the rodent brain (mainly the prefrontal cortex and hippocampus). Such artificially induced dysfunctions approximately correspond to the lesions found in patients with schizophrenia. However, notably, animal models of mental illness have numerous limitations and never fully reflect the disease state observed in humans.


Subject(s)
Antipsychotic Agents , Schizophrenia , Animals , Antipsychotic Agents/adverse effects , Behavior, Animal , Disease Models, Animal , Hippocampus , Humans , Prefrontal Cortex , Schizophrenia/drug therapy
3.
Neurotox Res ; 39(6): 1747-1761, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34665405

ABSTRACT

MK-801, as an N-methyl-D-aspartate (NMDA) receptor inhibitor, causes elevation in glutamate release, which may lead to an increase in excitotoxicity, oxidative stress and, consequently, cell death. 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) shows antioxidant activity. The aim of the present study was to evaluate the effect of combined treatment with 1MeTIQ and MK-801 on cell viability, antioxidant enzyme activity, and glutamate release in the rat hippocampus. Cytotoxicity was measured using lactate dehydrogenase leakage assay (LDH) and the methyl tetrazolium (MTT) assay; antioxidant enzyme activity (glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), and catalase (CAT)) were measured by ELISA kits. The release of glutamate in the rat hippocampus was measured using in vivo microdialysis methodology. An in vitro study showed that MK-801 induced cell death in a concentration-dependent manner and that 1MeTIQ partially reduced this adverse effect of MK-801. An ex vivo study indicated that MK-801 produced an increase in antioxidant enzyme activity (GPx, GR, and SOD), whereas coadministration of MK-801 and 1MeTIQ restored the activity of these enzymes to the control level. An in vivo microdialysis study demonstrated that combined treatment with both drugs decreased the release of glutamate in the rat hippocampus. The above results revealed that 1MeTIQ shows limited neuroprotective activity under conditions of glutamate-induced neurotoxicity.


Subject(s)
Cell Survival/drug effects , Dizocilpine Maleate/pharmacology , Glutamic Acid/metabolism , Hippocampus/drug effects , Isoquinolines/pharmacokinetics , Oxidative Stress/drug effects , Animals , Catalase/metabolism , Dizocilpine Maleate/administration & dosage , Glutathione Reductase/metabolism , Hippocampus/metabolism , Isoquinolines/administration & dosage , L-Lactate Dehydrogenase/metabolism , Male , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/metabolism
4.
Pharmacol Rep ; 73(2): 490-505, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33403530

ABSTRACT

BACKGROUND: The aim of the present study was to evaluate the effect of 1MeTIQ on fear memory and social interaction in an MK-801-induced model of schizophrenia. The results obtained after administration of 1MeTIQ were compared with those obtained with olanzapine, an antipsychotic drug. METHODS: Sprague-Dawley rats received a single injection of MK-801 to induce behavioral disorders. 1MeTIQ was given either acutely in a single dose or chronically for 7 consecutive days. Olanzapine was administered once. In groups receiving combined treatments, 1MeTIQ or olanzapine was administered 20 min before MK-801 injection. Contextual fear conditioning was used to assess disturbances in fear memory (FM), and the sociability of the rats was measured in the social interaction test (SIT). Biochemical analysis was carried out to evaluate monoamine levels in selected brain structures after treatment. RESULTS: Our results are focused mainly on data obtained from neurochemical studies, demonstrating that 1MeTIQ inhibited the MK-801-induced reduction in dopamine levels in the frontal cortex and increased the 5-HT concentration. The behavioral tests revealed that acute administration of MK-801 caused disturbances in both the FM and SIT tests, while neither 1MeTIQ nor olanzapine reversed these deficits. CONCLUSION: 1MeTIQ, although pharmacologically effective (i.e., it reverses MK-801-induced changes in monoamine activity), did not influence MK-801-induced social and cognitive deficits. Thus, our FM tests and SIT did not support the main pharmacological hypotheses that focus on dopamine system stabilization and dopamine-serotonin system interactions as probable mechanisms for inhibiting the negative symptoms of schizophrenia.


Subject(s)
Antipsychotic Agents/pharmacology , Olanzapine/pharmacology , Schizophrenia/drug therapy , Tetrahydroisoquinolines/pharmacology , Animals , Disease Models, Animal , Dizocilpine Maleate/toxicity , Dopamine/metabolism , Dopamine Antagonists/pharmacology , Fear/drug effects , Male , Rats , Rats, Sprague-Dawley , Schizophrenia/physiopathology , Social Interaction , Tetrahydroisoquinolines/administration & dosage
5.
Behav Brain Res ; 393: 112769, 2020 09 01.
Article in English | MEDLINE | ID: mdl-32535184

ABSTRACT

According to preclinical and clinical studies, the antidepressant-induced increase in the activity of atypical antipsychotics may efficiently improve the treatment of negative and some cognitive symptoms of schizophrenia. In the present study, we aimed to evaluate the effects of the antidepressants escitalopram and mirtazapine and the atypical antipsychotic drug aripiprazole, administered separately or in combination, on the MK-801-induced deficits in the recognition memory test and on the extracellular levels of monoamines and their metabolites in the rat frontal cortex. Based on the results of the behavioral tests, co-treatment with an ineffective dose of aripiprazole (0.1 mg/kg) and escitalopram (2.5 and 5 mg/kg) or mirtazapine (5 mg/kg) abolished the deficits evoked by MK-801 in the novel object recognition test, and those effects were blocked by the 5-HT1A receptor antagonist (WAY 100,635) or the dopamine D1 receptor antagonist (SCH 23,390). Moreover, co-treatment with aripiprazole (0.3 mg/kg) and escitalopram (5 mg/kg) significantly increased the levels of noradrenaline and serotonin, decreased the level of its metabolite, and did not alter level of dopamine, but decreased the levels of its metabolites. In addition, co-treatment with aripiprazole (0.3 mg/kg) and mirtazapine (10 mg/kg) significantly increased the level of noradrenaline, did not change the levels of dopamine and serotonin, but increased the levels of their metabolites. Based on these results, the increase in the extracellular levels of noradrenaline or serotonin in the cortex induced by co-treatment with an antidepressant and aripiprazole may be very important for the pharmacotherapy of negative and some cognitive symptoms of schizophrenia.


Subject(s)
Antidepressive Agents/pharmacology , Aripiprazole/pharmacology , Biogenic Monoamines/metabolism , Frontal Lobe/drug effects , Memory Disorders/drug therapy , Recognition, Psychology/drug effects , Animals , Antidepressive Agents/therapeutic use , Aripiprazole/therapeutic use , Benzazepines/pharmacology , Citalopram/pharmacology , Citalopram/therapeutic use , Dizocilpine Maleate , Dopamine Antagonists/pharmacology , Frontal Lobe/metabolism , Memory Disorders/chemically induced , Memory Disorders/metabolism , Piperazines/pharmacology , Pyridines/pharmacology , Rats , Serotonin Antagonists/pharmacology
6.
Psychopharmacology (Berl) ; 237(6): 1577-1593, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32076746

ABSTRACT

RATIONALE: Schizophrenia is a mental illness which is characterised by positive and negative symptoms and by cognitive impairments. While the major prevailing hypothesis is that altered dopaminergic and/or glutamatergic transmission contributes to this disease, there is evidence that the noradrenergic system also plays a role in its major symptoms. OBJECTIVES: In the present paper, we investigated the pro-cognitive effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) an endogenous neuroprotective compound, on ketamine-modelled schizophrenia in rats. METHODS: We used an antagonist of NMDA receptors (ketamine) to model memory deficit symptoms in rats. Using the novel object recognition (NOR) test, we investigated the pro-cognitive effect of 1MeTIQ. Additionally, olanzapine, an atypical antipsychotic drug, was used as a standard to compare the pro-cognitive effects of the substances. In vivo microdialysis studies allowed us to verify the changes in the release of monoamines and their metabolites in the rat striatum. RESULTS: Our study demonstrated that 1MeTIQ, similarly to olanzapine, exhibits a pro-cognitive effect in NOR test and enhances memory disturbed by ketamine treatment. Additionally, in vivo microdialysis studies have shown that ketamine powerfully increased noradrenaline release in the rat striatum, while 1MeTIQ and olanzapine completely antagonised this neurochemical effect. CONCLUSIONS: 1MeTIQ, as a possible pro-cognitive drug, in contrast to olanzapine, expresses beneficial neuroprotective activity in the brain, increasing concentration of the extraneuronal dopamine metabolite, 3-methoxytyramine (3-MT), which plays an important physiological role in the brain as an inhibitory regulator of catecholaminergic activity. Moreover, we first demonstrated the essential role of noradrenaline release in memory disturbances observed in the ketamine-model of schizophrenia, and its possible participation in negative symptoms of the schizophrenia.


Subject(s)
Ketamine/toxicity , Motor Activity/drug effects , Nootropic Agents/therapeutic use , Schizophrenia/chemically induced , Schizophrenia/drug therapy , Tetrahydroisoquinolines/therapeutic use , Animals , Antipsychotic Agents/pharmacology , Antipsychotic Agents/therapeutic use , Brain/drug effects , Brain/metabolism , Corpus Striatum/drug effects , Dopamine/analogs & derivatives , Dopamine/metabolism , Excitatory Amino Acid Antagonists/toxicity , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Male , Microdialysis , Motor Activity/physiology , Nootropic Agents/pharmacology , Norepinephrine/metabolism , Rats , Rats, Sprague-Dawley , Rats, Wistar , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Tetrahydroisoquinolines/pharmacology , Treatment Outcome
7.
Pharmacol Biochem Behav ; 181: 17-27, 2019 06.
Article in English | MEDLINE | ID: mdl-30965047

ABSTRACT

Anxiety is a common symptom of schizophrenia. Ketamine, which acts as a noncompetitive antagonist of glutamatergic NMDA receptors by binding to the phencyclidine site, may induce schizophrenia-like symptoms and promote anxiogenic-like behaviour. The symptoms of anxiety in rodents can be measured by the elevated plus maze (EPM) test. 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), as a neuroprotective and antiaddictive substance, produces pharmacological effects by influencing monoaminergic and glutamatergic activity, as previously demonstrated by us. The aim of the present study was to investigate the anxiolytic-like potential of 1MeTIQ after the administration of ketamine. These results were compared to the effects of olanzapine, an antipsychotic drug commonly used in the treatment of schizophrenia. We conducted the EPM test, during which the percentage of time spent in and the number of entries into the open arms were measured. In addition, locomotor activity was measured. Furthermore, we conducted biochemical analyses to verify changes in the levels of neurotransmitters and their metabolites in selected rat brain structures. Behavioural analyses showed that 1MeTIQ, similar to olanzapine, completely inhibited ketamine-induced anxiogenic effects in the EPM test. On the other hand, neurochemical data indicated that 1MeTIQ, as a reversible inhibitor of MAO, significantly blocked the dopamine MAO-dependent oxidation pathway, whereas olanzapine significantly increased the activity of this pathway. The results above suggest that the anxiolytic-like properties of 1MeTIQ are connected to its influence on the catabolism of dopamine, the elevation of serotonin concentrations and the reduction in the levels of noradrenaline.


Subject(s)
Antipsychotic Agents/pharmacology , Brain/drug effects , Dopamine Antagonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Ketamine/pharmacology , Maze Learning/drug effects , Monoamine Oxidase Inhibitors/pharmacology , Olanzapine/pharmacology , Tetrahydroisoquinolines/pharmacology , Analysis of Variance , Animals , Anxiety/chemically induced , Anxiety/drug therapy , Behavior, Animal/drug effects , Dopamine/metabolism , Locomotion/drug effects , Male , Norepinephrine/metabolism , Oxidation-Reduction/drug effects , Rats , Rats, Sprague-Dawley , Serotonin/metabolism
8.
Cancer Lett ; 381(2): 323-30, 2016 10 28.
Article in English | MEDLINE | ID: mdl-27502168

ABSTRACT

Antibody-drug conjugates (ADCs) combine the potency of cytotoxic drugs with the specificity of monoclonal antibodies (mAbs). Most ADCs are currently generated by the nonspecific conjugation of drug-linker reagents to certain amino acid residues in mAbs, resulting in a heterogeneous product. To overcome this limitation and prepare ADCs with a defined stoichiometry, we use SNAP-tag technology as an alternative conjugation strategy. This allows the site-specific conjugation of O(6)-benzylguanine (BG)-modified small molecules to SNAP-tag fusion proteins. To demonstrate the suitability of this system for the preparation of novel recombinant ADCs, here we conjugated SNAP-tagged single chain antibody fragments (scFvs) to a BG-modified version of auristatin F (AURIF). We used two scFv-SNAP fusion proteins targeting members of the epidermal growth factor receptor (EGFR) family that are frequently overexpressed in breast cancer. The conjugation of BG-AURIF to EGFR-specific 425(scFv)-SNAP and HER2-specific αHER2(scFv)-SNAP resulted in two potent recombinant ADCs that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations. These data confirm that SNAP-tag technology is a promising tool for the generation of novel recombinant ADCs.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , ErbB Receptors/immunology , Guanine/analogs & derivatives , Immunotherapy/methods , Immunotoxins/pharmacology , Oligopeptides/pharmacology , Q-SNARE Proteins/pharmacology , Receptor, ErbB-2/immunology , Single-Chain Antibodies/pharmacology , Animals , Apoptosis/drug effects , Breast Neoplasms/immunology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Stability , ErbB Receptors/metabolism , Guanine/pharmacology , Humans , Immunotoxins/immunology , Inhibitory Concentration 50 , Mice , Q-SNARE Proteins/immunology , Receptor, ErbB-2/metabolism , Recombinant Fusion Proteins/pharmacology , Signal Transduction/drug effects , Single-Chain Antibodies/immunology
9.
Monoclon Antib Immunodiagn Immunother ; 35(3): 141-7, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27187007

ABSTRACT

SNAP-tag technology allows recombinant proteins to be covalently labeled to O(6)-benzylguanine (BG)-modified substrates with 1:1 stoichiometry. By attaching according fluorophores, this method is ideally suited for in vitro and in vivo imaging, as well as protein interaction analyses. Fluorophores modified with BG react with the SNAP-tag, whereas those modified with O(2)-benzylcytosine (BC) conjugate to a more recent derivative known as the CLIP-tag. The orthogonal substrate specificity of the SNAP- and CLIP-tags extends the range of applications by allowing double labeling. We previously developed a monoclonal antibody (mAb) that recognizes both tags. In this study, we describe a new mAb, which is specific for the SNAP-tag alone. Therefore, this mAb allows discrimination between SNAP- and CLIP-tags within a broad range of immunological methods, including enzyme-linked immunosorbent assays, western blotting, flow cytometry, and immunohistochemistry.


Subject(s)
Antibodies, Monoclonal/immunology , Guanine/analogs & derivatives , Recombinant Fusion Proteins/isolation & purification , Antibodies, Monoclonal/chemistry , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Fluorescent Dyes/chemistry , Guanine/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology
10.
Monoclon Antib Immunodiagn Immunother ; 33(6): 369-77, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25545205

ABSTRACT

Monoclonal antibodies are produced in cultured hybridoma cell lines, but these cells tend to be unstable; it is therefore necessary to rescue the corresponding genetic information. Here we describe an improved method for the amplification of antibody variable gene (V-gene) information from murine hybridoma cells using a panel of specific, non-degenerate primers. This primer set allows sequences to be rescued from all murine V-genes, except the lambda light chain genes, which rarely contribute to murine immune diversity. We tested the primers against a range of antibodies and recovered specific amplification products in all cases. The heavy and light chain variable regions were subsequently joined by a two-step cloning strategy or by splice overlap extension PCR.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/genetics , DNA Primers/genetics , Hybridomas/immunology , Immunoglobulin Variable Region/genetics , Recombinant Proteins/genetics , Animals , Antibodies, Monoclonal, Murine-Derived/immunology , Base Sequence , Blotting, Western , Cell Line , Cloning, Molecular/methods , DNA, Complementary/biosynthesis , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Genetic Vectors/genetics , HEK293 Cells , Humans , Mice , Molecular Sequence Data , Polymerase Chain Reaction , Recombinant Proteins/immunology , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL
...